Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jörg H. W. Distler is active.

Publication


Featured researches published by Jörg H. W. Distler.


Journal of Immunology | 2006

The Potential of Adiponectin in Driving Arthritis

Angela Ehling; Andreas Schäffler; Hans Herfarth; Ingo H. Tarner; Sven Anders; Oliver Distler; G. Paul; Jörg H. W. Distler; Jürgen Schölmerich; Elena Neumann; Ulf Müller-Ladner

Articular adipose tissue is a ubiquitous component of human joints, but its local functions are largely unknown. Because recent studies revealed several links between adipose tissue, adipocytokines, and arthritis, we investigated the expression of the adipocytokine adiponectin and its functional role in articular adipose tissue and synovium of patients with different arthritides. In contrast to its protective role in endocrinological and vascular diseases, adiponectin was found to be involved in key pathways of inflammation and matrix degradation in the human joint. The effects of adiponectin in human synovial fibroblasts appear to be highly selective by inducing only two of the main mediators of rheumatoid arthritis pathophysiology, IL-6 and matrix metalloproteinase-1, via the p38 MAPK pathway. Owing to the observation that these effects could be inhibited by different TNF-α inhibitors, adipocytokines such as adiponectin may also be key targets for therapeutic strategies in inflammatory joint diseases. In summary, articular adipose tissue and adipocytokines cannot be regarded as innocent bystanders any more in chronic inflammatory diseases such as arthritis.


Apoptosis | 2007

The role of membrane lipids in the induction of macrophage apoptosis by microparticles

Lars C. Huber; Astrid Jüngel; Jörg H. W. Distler; Falk Moritz; Beat A. Michel; David S. Pisetsky; Oliver Distler

Microparticles are membrane-derived vesicles that are released from cells during activation or cell death. These particles can serve as mediators of intercellular cross-talk and induce a variety of cellular responses. Previous studies have shown that macrophages undergo apoptosis after phagocytosing microparticles. Here, we have addressed the hypothesis that microparticles trigger this process via lipid pathways. In these experiments, microparticles induced apoptosis in primary macrophage cells or cell lines (RAW 264.7 or U937) with up to a 5-fold increase. Preincubation of macrophages with phosphatidylinositol-3,5-bisphosphate (PtdIns(3,5)BP) reduced the microparticle-induced apoptosis in a dose-dependent manner. PtdIns(3,5)BP is a specific inhibitor of the acid sphingomyelinase and thus can block the generation of pro-apoptotic ceramides. Similarly, the pre-incubation of macrophages with PtdIns(3,5)BP prevented microparticle-induced upregulation of caspase 8, which is a major target molecule of ceramide action in the apoptosis pathway. PtdIns(3,5)BP, however, had no effect on the spontaneous rate of apoptosis. To evaluate further signaling pathways induced by microparticles, the extracellular signal regulated kinase (ERK-) 1 was investigated. This kinase plays a role in activating phospholipases A2 which cleaves membrane phospholipids into arachidonic acid; microparticles have been suggested to be a preferred substrate for phospholipases A2. As shown in our experiments, microparticles strongly increased the amount of phosphorylated ERK1/2 in RAW 264.7 macrophages in a time-dependent manner, peaking 15 min after co-incubation. Addition of PD98059, a specific inhibitor of ERK1, prevented the increase in apoptosis of RAW 264.7 macrophages. Together, these data suggest that microparticles perturb lipid homeostasis of macrophages and thereby induce apoptosis. These results emphasize the importance of biolipids in the cellular cross-talk of immune cells. Based on the fact that in clinical situations with excessive cell death such as malignancies, autoimmune diseases and following chemotherapies high levels of circulating microparticles might modulate phagocytosing cells, a suppression of the immune response might occur due to loss of macrophages.


Experimental Dermatology | 2005

Nucleofection: a new, highly efficient transfection method for primary human keratinocytes*

Jörg H. W. Distler; Astrid Jüngel; Mariola Kurowska-Stolarska; Beat A. Michel; Oliver Distler

Abstract:  Transfection is an essential tool for numerous in vitro applications including studies of gene expression, promoter analysis, and intracellular signaling pathways and also for therapeutic strategies such as tissue engineering and gene therapy. However, transfection of primary cells including keratinocytes with common methods such as calcium phosphate, DEAE‐dextran, liposome‐mediated transfer, electroporation or viral vectors is problematic because of low transfection efficiency and the induction of terminal differentiation. Here we analyzed the use of nucleofection, a new, electroporation‐based transfection method that enables the DNA to enter directly the nucleus, for the transfection of keratinocytes. Several different conditions were tested and optimized, resulting in a final transfection efficiency of 56% in primary human epidermal keratinocytes. This efficiency is superior to all non‐viral transfection methods reported so far. The number of non‐viable keratinocytes after nucleofection was low, varying between 14 and 16%. In contrast to other transfection protocols, nucleofection did not induce terminal differentiation in the transfected keratinocytes. In addition, nucleofection is a fast method, because the results can be analyzed within 7 h. In summary, nucleofection is a fast, easy and highly effective alternative for the transfection of primary human keratinocytes, which offers new opportunities for various research applications.


Arthritis & Rheumatism | 2009

Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast–dependent osteoclastogenesis

Mariola Kurowska-Stolarska; Jörg H. W. Distler; Astrid Jüngel; Weronika Rudnicka; Elena Neumann; Thomas Pap; Roland H. Wenger; Beat A. Michel; Ulf Müller-Ladner; Wlodzimierz Maslinski; Oliver Distler

OBJECTIVE To map hypoxic areas in arthritic synovium and to establish the relevance of low oxygen levels to the phenotype of synovial fibroblasts, with special focus on bone degradation. METHODS To analyze the distribution of hypoxia in arthritic joints, the hypoxia marker EF5 was administered to mice with collagen-induced arthritis (CIA). To evaluate the effect of hypoxia on rheumatoid arthritis synovial fibroblasts (RASFs), reverse suppression subtractive hybridization and complementary DNA array were used. Real-time polymerase chain reaction, Western blotting, and immunohistochemistry were used to evaluate the expression of inhibitor of DNA binding/differentiation 2 (ID-2). To investigate the function of ID-2 in RASFs, cells were transfected either with ID-2 vector or with ID-2-specific small interfering RNA. RESULTS EF5 staining showed the presence of hypoxia in arthritic joints, particularly at sites of synovial invasion into bone. Differential expression analysis revealed that ID-2 was strongly induced by hypoxia in RASFs. Immunohistochemical analysis of CIA mouse synovium and human RA synovium showed a strong expression of ID-2 by RASFs at sites of synovial invasion into bone. Overexpression of ID-2 in RASFs significantly induced the expression of several factors promoting osteoclastogenesis. The biologic relevance of the potent osteoclastogenesis-promoting effects was shown by coculture assays of ID-2-overexpressing RASFs with bone marrow cells, leading to an increased differentiation of osteoclasts from bone marrow precursors. CONCLUSION The data show that hypoxic conditions are present at sites of inflammation and synovial invasion into bone in arthritic synovium. Hypoxia-induced ID-2 may contribute to joint destruction in RA patients by promoting synovial fibroblast-dependent osteoclastogenesis.


Modern Rheumatology | 2002

Chemokines and chemokine receptors in the pathogenesis of systemic sclerosis.

Oliver Distler; Jörg H. W. Distler; Otylia Kowal-Bielecka; Ulf Müller-Ladner

Abstract  Activation of the immune system and increased synthesis of extracellular matrix proteins by fibroblasts are hallmarks in the pathogenesis of systemic sclerosis (SSc). The mechanisms that initiate the accumulation of inflammatory cells are still unknown. Chemokines are a family of small molecules that are divided into subfamilies according to the position of NH2-terminal cysteine motif. A new nomenclature for chemokines recently has been introduced in an attempt to overcome the confusion resulting from a number of different names for the same chemokines. Recent data indicate that chemokines, and in particular MCP-1 (CCL2), might be involved in the pathogenesis of SSc at different levels. MCP-1 is highly upregulated in skin specimens from SSc patients compared with those from healthy controls. Dermal fibroblasts release MCP-1, which is able to induce and perpetuate the migration of inflammatory cells into the skin. Interestingly, data from animal models, as well as from in vitro studies, indicate that MCP-1 might also be involved in the increased synthesis of extracellular matrix proteins, by either direct or indirect mechanisms. In conclusion, chemokines represent interesting candidates for target-directed therapies for SSc. This concept has to be confirmed by further studies using animal models for SSc and other fibrotic diseases.


Journal of Scleroderma and Related Disorders | 2016

Effect of endothelin-1 receptor antagonists on skin fibrosis in scleroderma patients from the EUSTAR database

Suzana Jordan; Jörg H. W. Distler; Britta Maurer; Ulrich A. Walker; Doerte Huscher; Yannick Allanore; Gabriela Riemekasten; Oliver Distler

Introduction The aim of the study was to evaluate the effect of endothelin-1 receptor antagonists (ETRAs) on skin fibrosis in systemic sclerosis (SSc) patients from the (EULAR Scleroderma Trials and Research) EUSTAR cohort. Methods SSc patients from the EUSTAR cohort with at least three visits (pre-study visit without ETRA treatment, baseline and follow-up visit with ETRA treatment) were included. The control group consisted of SSc patients with the same inclusion criteria, but without ETRA treatment. The primary endpoint was the comparison of the delta change of the modified Rodnan skin score (mRSS) between baseline and follow-up in the ETRA versus the control group. Results Data on 75 ETRA treated (68 bosentan, 1 sitaxentan, 6 ambrisentan) and 969 control patients were included. The delta change of mRSS was not significantly different between the ETRA group and the control group (n = 969; 0 (-2-1) vs. n = 75; 0 (-2-1); p = 0.4). Similarly, subgroup analysis on patients with diffuse, extended SSc disease (mRSS ≥16) did not show differences in the delta change of mRSS between the ETRA group and the control group (n = 125; −1 [-7-0] vs. n = 23; −1 [-7-2], p = 0.8). Likewise, diffuse SSc patients with mRSS 7-21 at baseline, reflecting recently identified enrichment criteria for clinical trials, did not show any difference between the ETRA and the control group (n = 219; −1 [-3-1] vs. n = 27; −1 [-3-2]; p = 0.5). Conclusions This controlled, observational, real-life cohort study with a large sample size did not show effects of ETRAs on skin fibrosis in patients with SSc.


Journal of Investigative Dermatology | 2018

Notch-signaling activity determines uptake and biological effect of imatinib in systemic sclerosis dermal fibroblasts.

Saliha Harrach; Vivien Barz; Thomas Pap; Hermann Pavenstädt; Eberhard Schlatter; Bayram Edemir; Jörg H. W. Distler; Giuliano Ciarimboli; Jessica Bertrand

Tyrosine kinase inhibitors have emerged as a therapeutic option for rheumatic diseases such as systemic sclerosis (SSc). Because tyrosine kinases like c-Abl kinase are important for fibroblast activation and fibrosis development in SSc, the c-Abl inhibitor imatinib was proposed for SSc treatment. Transporters for organic cations have become increasingly recognized as an important determinant for uptake and efficacy of tyrosine kinase inhibitors. Therefore, we investigated the role of organic cation transporters in the uptake of imatinib. Moreover, the influence of important SSc pathogenetic factors, like PDGF and Notch pathway activation on these uptake processes, has been studied. We showed that organic cation transporters OCT1-3, novel organic cation transporters OCTN1/2, and the multidrug and toxin extrusion protein MATE1 are expressed in healthy dermal and SSc fibroblasts. Decreased expression levels of MATE1 and decreased imatinib uptake were measured in SSc fibroblasts. In small interfering RNA experiments, MATE1 was identified as key transporter for imatinib uptake and biological effect in dermal fibroblasts. Furthermore, PDGF reduced imatinib uptake by decreasing MATE1 expression in SSc fibroblasts, but not in healthy fibroblasts. Blocking the Notch pathway in SSc fibroblasts increased MATE1 transporter expression and imatinib uptake. In conclusion, MATE1-mediated transport governs therapeutic efficacy of imatinib in SSc.


The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine | 2003

Angiogenic and angiostatic factors in the molecular control of angiogenesis

Jörg H. W. Distler; A. Hirth; Mariola Kurowska-Stolarska; Oliver Distler


Arthritis & Rheumatism | 2005

Microparticles as regulators of inflammation: Novel players of cellular crosstalk in the rheumatic diseases

Jörg H. W. Distler; David S. Pisetsky; Lars C. Huber; Joachim R. Kalden; Oliver Distler


Arthritis & Rheumatism | 2007

Histone Deacetylase/Acetylase Activity in Total Synovial Tissue Derived From Rheumatoid Arthritis and Osteoarthritis Patients

Lars C. Huber; Matthias Brock; Hossein Hemmatazad; Olivier T. Giger; Falk Moritz; Michelle Trenkmann; Jörg H. W. Distler; Christoph Kolling; Holger Moch; Beat A. Michel; Oliver Distler; Astrid Jüngel

Collaboration


Dive into the Jörg H. W. Distler's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Thomas Pap

Otto-von-Guericke University Magdeburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge